Skip to content

US · OMCL · MEDICAL - EQUIPMENT & SERVICES

Omnicell, Inc. (OMCL) intrinsic value and stock valuation

$32.51as of 2026-11-21 · Mkt cap 1.67B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Omnicell, Inc. DCF and intrinsic value

InvestorsCraft values OMCL with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from OMCL’s statements →

Omnicell, Inc. Graham Number

Graham Number: $5.19d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Equipment & Services Fort Worth, TX 76137 omnicell.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$1.18B+5.8% 5y CAGRd
20112025
Net income
$2.05M-42.3% 5y CAGRd
20112025
Free cash flow
$86.9M-7.9% 5y CAGRd
20112025
Total equity
$1.23B+4.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$1.18B$1.11B$1.15B$1.3B$1.13B
Operating income$11.7M$340K-$-19.33M-$-2.32M$89.5M
Net income$2.05M$12.5M-$-20.37M$5.65M$77.9M
EPSd$44.2K$270.9K-$-450.56K$123.1K$1.62M
Operating cash flow$127.3M$187.7M$181.1M$77.8M$231.8M
Capital expenditure-$-40.41M-$-36.46M-$-41.47M-$-60.74M-$-28.97M
Free cash flow$86.9M$151.3M$139.6M$17M$202.8M
Total assets$1.97B$2.12B$2.23B$2.21B$2.14B
Total debt$204.3M$382.6M$614.1M$616.7M$541M
Net debt$7.83M$13.4M$146.1M$286.4M$192M
Total equity$1.23B$1.24B$1.19B$1.13B$1.15B
Cash and short-term investments$211.2M$381.7M$479.8M$341.9M$359.7M
Income statement
20252024202320222021
Revenue$1.18B$1.11B$1.15B$1.3B$1.13B
Cost of revenue$676.8M$641.2M$647.2M$707M$577.4M
Gross profit$508M$471M$499.9M$589M$554.7M
Research and development expenses$87.7M$90.4M$93.3M$105M$75.7M
Selling, general and administrative expenses$408.6M$380.3M$426M$486.3M$389.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$496.4M$470.7M$519.3M$591.3M$465.2M
Cost and expenses$1.17B$1.11B$1.17B$1.3B$1.04B
Interest income$11.9M$24.9M$14.8M$0.00$0.00
Interest expense$3.91M$4.53M$0.00$130K$22.4M
Depreciation and amortization$86.6M$89.8M$95.6M$99.2M$84.9M
Ebitda$101.9M$119.9M$80M$96.9M$173.3M
Operating income$11.7M$340K-$-19.33M-$-2.32M$89.5M
Total other income/expenses, net-$-340K$25.3M-$-780K-$-130K-$-23.5M
Income before tax$11.3M$25.6M-$-20.11M-$-2.45M$66M
Income tax expense$9.27M$13.1M$260K-$-8.1M-$-11.84M
Net income$2.05M$12.5M-$-20.37M$5.65M$77.9M
Weighted average shares outstanding$46M$46.1M$45.2M$44.4M$43.5M
Weighted average diluted shares outstanding$46.4M$46.3M$45.2M$45.9M$47.9M
Balance sheet
20252024202320222021
Cash and short-term investments$211.2M$381.7M$479.8M$341.9M$359.7M
Net receivables$216.9M$256.4M$252M$299.5M$240.9M
Inventory$100.9M$88.7M$110.1M$147.6M$119.9M
Total current assets$680.1M$815.5M$927.6M$881.8M$780.7M
Property, plant and equipment, net$144.5M$138.3M$133.6M$132M$119.7M
Goodwill and intangible assets$962.3M$981.4M$1.01B$1.06B$1.11B
Long-term investments$60.7M$52.7M$43M$32.9M$18.4M
Total non-current assets$1.29B$1.31B$1.3B$1.33B$1.36B
Total assets$1.97B$2.12B$2.23B$2.21B$2.14B
Accounts payable$44M$51.8M$45M$63.4M$71.5M
Short-term debt$12M$185M$10.5M$10.8M$501.1M
Deferred revenue$283.5M$202M$175.9M$187.2M$152.1M
Total current liabilities$476.6M$595.7M$367.8M$428.5M$876.2M
Long-term debt$192.4M$197.5M$603.6M$606M$39.9M
Deferred revenue, non-current$63.3M$76.1M$58.6M$37.4M$20.2M
Total non-current liabilities$266.3M$282M$670.1M$652.2M$119.7M
Capital lease obligations$36.8M$41.8M$44.4M$50.2M$52.9M
Total liabilities$742.9M$877.7M$1.04B$1.08B$995.8M
Common stock$60K$60K$60K$60K$50K
Retained earnings$384.9M$382.9M$370.4M$390.7M$368.6M
Accumulated other comprehensive income (loss)-$-8.85M-$-17.2M-$-13.43M-$-17.09M-$-8.41M
Total equity$1.23B$1.24B$1.19B$1.13B$1.15B
Total investments$75.4M$65.2M$54.8M$44.4M$29.1M
Total debt$204.3M$382.6M$614.1M$616.7M$541M
Net debt$7.83M$13.4M$146.1M$286.4M$192M
Cash flow statement
20252024202320222021
Net income$2.05M$12.5M-$-20.37M$5.65M$77.9M
Depreciation and amortization$86.6M$89.8M$95.6M$99.2M$84.9M
Stock-based compensation$44.5M$39.3M$55.3M$68.3M$53.2M
Change in working capital-$-8.33M$58.3M$43.7M-$-73.47M-$-3.34M
Accounts receivable$41.4M-$-5M$38.7M-$-60.36M-$-40.97M
Inventory-$-11.22M$5.39M$38M-$-30.11M-$-25.7M
Accounts payable-$-9.28M$7.21M-$-17.52M-$-7.75M$29.1M
Net cash provided by operating activities$127.3M$187.7M$181.1M$77.8M$231.8M
Investments in property, plant and equipment-$-40.41M-$-36.46M-$-55.02M-$-60.74M-$-28.97M
Acquisitions, net$0.00$0.00$0.00$2.07M-$-354.16M
Net cash used for investing activities-$-60.36M-$-52.79M-$-55.02M-$-58.67M-$-412.5M
Common stock issued$16.9M$38.6M$23.2M$40.2M$0.00
Common stock repurchased-$-77.6M$0.00$0.00-$-52.21M-$-16.29M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-218.32M-$-235.58M$23.4M-$-20.95M$47.4M
Net change in cash-$-147.58M-$-102.36M$148.1M-$-2.79M-$-134.3M
Cash at end of period$251M$398.6M$501M$352.8M$355.6M
Operating cash flow$127.3M$187.7M$181.1M$77.8M$231.8M
Capital expenditure-$-40.41M-$-36.46M-$-41.47M-$-60.74M-$-28.97M
Free cash flow$86.9M$151.3M$139.6M$17M$202.8M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Omnicell, Inc.

        Omnicell, Inc., together with its subsidiaries, provides healthcare technology in the United States and internationally. It offers hospital and health systems solutions, such as points of care for clinician workflows in patient care areas of the healthcare system; Titan XT, an automated dispensing system; XTExtend, a console swap for its XT cabinets; and Central Pharmacy Dispensing Service for the medication dispensing process. The company also provides Central Med Automation Service for medication dispensing; IV Compounding Service, an in-house compounding system; specialty pharmacy services, including turnkey solution to help health systems establish, manage, and optimize an entity-owned specialty pharmacy; EnlivenHealth platform to digitally enable retail and community pharmacies; medication adherence solutions comprising consumables and medication packaging systems; and technology implementation, customer education and training, program management, and related offerings to professional services. In addition, it offers post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; software and hardware products for full traceability of medicines and medical supplies throughout the healthcare system; OmniSphere, a cloud-based platform. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

        CEO
        Randall A. Lipps
        Employees
        3.58K
        Beta
        0.97

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Omnicell, Inc. (OMCL)?

        Omnicell, Inc. (OMCL) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is OMCL undervalued?

        OMCL trades at a price of $32.51 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.